A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma

This publication has 10 references indexed in Scilit:

• The influence of high dose hydroxyurea on the incorporation of 5-iodo-2-deoxyuridine (IUdR) by human bone marrow and tumour cells in vivo
  British Journal of Cancer, 1993
• Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma—an effective combination with unexpected toxicity
  European Journal Of Cancer, 1992
• Repair of DNA containing O ⁶ ‐alkylguanine
  The FASEB Journal, 1992
• Induction and time course of DNA single-strand breaks in lymphocytes from patients treated with dacarbazine
  Carcinogenesis: Integrative Cancer Research, 1991
• Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma
  Cancer, 1989
• Phase 1 study of high-dose hydroxyurea in lung cancer
  Cancer Chemotherapy and Pharmacology, 1988
• Cytotoxicity of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide
  British Journal of Cancer, 1987
• Inhibition of poly(ADP-ribose) synthetase potentiates cell dacarbazine cytotoxicity
  Biochemical and Biophysical Research Communications, 1987
• In vivo metabolism and reaction with dna of the cytostatic agent, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC)
  Biochemical Pharmacology, 1986
• Alteration of DNA by 5-(3-methyl-1- triazeno)imidazole-4-carboxamide (NSC-407347)
  Biochemical Pharmacology, 1976